Direkt zum Inhalt
Merck

04273

Sigma-Aldrich

Natriumphosphat dibasisch Dodecahydrat

meets analytical specification of Ph. Eur., BP, E339, 98.5-102.5% (T)

Synonym(e):

sec-Natriumphosphat, Dinatrium-hydrogenphosphat Dodecahydrat, Dinatriumphosphat, di-Natriumhydrogenphosphat Dodecahydrat

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Lineare Formel:
Na2HPO4 · 12H2O
CAS-Nummer:
Molekulargewicht:
358.14
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
12161700
PubChem Substanz-ID:
NACRES:
NA.25
Assay:
98.5-102.5% (T)
Form:
crystals

Agentur

meets analytical specifications of BP
meets analytical specifications of Ph. Eur.

Qualitätsniveau

Assay

98.5-102.5% (T)

Form

crystals

Qualität

meets analytical specification of Ph. Eur., BP, E339

Verunreinigungen

reducing matter, complies
residual solvents, complies
≤0.001% heavy metals (as Pb)
≤1.0% NaH2PO4
57-61% water (Karl Fischer)

Verlust

57-61% loss on drying

pH-Wert

8.4-9.6 (20 °C, 1%)

Anionenspuren

chloride (Cl-): ≤10 mg/kg
fluoride (F-): ≤10 mg/kg
sulfate (SO42-): ≤100 mg/kg

Kationenspuren

As: ≤1 mg/kg
Cd: ≤1 mg/kg
Cu: ≤20 mg/kg
Fe: ≤10 mg/kg
Hg: ≤1 mg/kg
K: ≤50 mg/kg
Pb: ≤4 mg/kg
Zn: ≤10 mg/kg

Eignung

complies for appearance of solution

SMILES String

O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O
O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

InChI

1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2

InChIKey

DGLRDKLJZLEJCY-UHFFFAOYSA-L

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung


  • Study of the Influence of Alkalizing Components on Matrix Pellets Prepared by Extrusion/Spheronization: This publication examines the effects of sodium phosphate dibasic dodecahydrate as an alkalizing agent in matrix pellets, showcasing its application in improving the physicochemical properties of pellets, which are crucial for controlled drug delivery systems (Hamedelniel EI, Bajdik J, Kasa P Jr, Pintye-Hodi K, 2012).

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Matthew H Crouthamel et al.
Arteriosclerosis, thrombosis, and vascular biology, 33(11), 2625-2632 (2013-08-24)
Elevated serum phosphate has emerged as a major risk factor for vascular calcification. The sodium-dependent phosphate cotransporter, PiT-1, was previously shown to be required for phosphate-induced osteogenic differentiation and calcification of cultured human vascular smooth muscle cells (VSMCs), but its
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
Luciano Candilio et al.
Heart (British Cardiac Society), 101(3), 185-192 (2014-09-26)
Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.